Phase 1 Single and Multiple Dose Clinical Trials (ASCENT‐1 and ASCENT‐2) for Dose‐Finding of PRX012 in Participants with Biologically Confirmed Alzheimer’s Disease
Chad Swanson, Ferenc Martényi, Ryan E Tooker, Brian M Campbell, Ann Johnson, Lingnan Li, Mary E Quiceno, Wagner M Zago, Gene G Kinney, Hideki Garren · 2025
Read Phase 1 Single and Multiple Dose Clinical Trials (ASCENT‐1 and ASCENT‐2) for Dose‐Finding of PRX012 in Participants with Biologically Confirmed Alzheimer’s Disease by Chad Swanson, Ferenc Martényi, Ryan E Tooker, Brian M Campbell, Ann Johnson, Lingnan Li, Mary E Quiceno, Wagner M Zago, Gene G Kinney, Hideki Garren (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713914.txt.
Description
Chad Swanson and nine co-authors lay out two early drug trials that seek the right dose of a new Alzheimer's drug, in a 2025 conference paper. The drug, PRX012, is an antibody that clears harmful forms of amyloid from the brain. It is given as a shot under the skin. New drugs of this class have already slowed decline in some patients.
The first trial gives a single shot to healthy adults and to patients whose disease is confirmed by scan, with doses rising step by step. The second gives repeat doses to patients and adds checks on how the drug acts in the body. Both trials track safety, body response, and how long the drug lasts. The work will set the dose for larger tests of whether the drug helps.
Catalog record
| CREATOR | Chad Swanson, Ferenc Martényi, Ryan E Tooker, Brian M Campbell, Ann Johnson, Lingnan Li, Mary E Quiceno, Wagner M Zago, Gene G Kinney, Hideki Garren |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |